TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter, Randomized, Open-Label, Parallel-Group Trial to Compare the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™)to Intravenous Patient-Controlled Analgesia With Morphine for the Treatment of Acute Post-Operative Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients who are 18 years or older~* Patients who are scheduled to undergo an open abdominal surgery (including laparoscopic-assisted), total knee or total hip replacement surgery under general anesthesia or spinal anesthesia that does not include intrathecal opioids during the operation.~* Post-surgical patients who have been admitted to the PACU and are expected to remain hospitalized and to have acute post-operative pain requiring parenteral opioids for at least 48 hours after surgery.~Exclusion Criteria:~* Patients who have taken an opioid for more than 30 consecutive days, at a daily dose of more than 15 mg of morphine (or equivalent), within the past 3 months prior to surgery (e.g. more than 3 doses per day of Vicodin®, Norco®, Lortab® with 5 mg hydrocodone per tablet).~* Patients with an allergy or hypersensitivity to opioids~* Female patients who are pregnant or breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sufentanil NanoTab PCA System/15 mcg (Type: EXPERIMENTAL): None
- morphine IV PCA (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Clinical Study for the Treatment of Cold Sore

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* History of recurrent herpes labialis lesions where:~  * At least 50% of previous episodes produced classical lesions to the vesicular stage (i.e. episodes that progressed through macula, papule, vesicle, crust and healed);~ * Prodromal symptoms (itching, tingling, pain etc.) should precede herpes labialis lesions in at least 50% of the previous herpes episodes~* Good general health (ECOG \< 2), immunocompetent~* Signed and dated written informed consent~* Women of childbearing potential must have effective contraception method~Exclusion Criteria:~* More than 50% of recurrences that aborted spontaneously in the past 12 months~* Primary herpes lesion outside the lips (e.g. nose, chin, etc.)~* Abnormal peri-oral skin condition that might affect the normal course of cold sores (e.g. eczema, psoriasis...)~* Oral diseases whose prodromal symptoms may mimick those of herpes labialis, including recurrent oral aphthous disease~* Oral diseases that might interfere with the evaluation of the efficacy or safety of the treatments, including gingivitis, parondotis, mucositis, oropharyngeal candidiasis...~* History of infection known to be resistant to acyclovir family agents~* Previous vaccination against herpes~* Concomitant treatment likely to interfere with acyclovir~* Allergy to any acyclovir containing agents~* Immunocompromised condition, including HIV+~* Unability to properly understand protocol requirements, to follow the study procedures, to complete the patient diary or to start the self-initiation of the treatment~* Upper full or partial dentures with acrylic border in the canine fossa~* Milk allergy or known history of hypersensitivity to one of the components of the products~* Rare hereditary problems of galactose intolerance.~* Lactase enzyme deficiency or glucose galactose malabsorption~* Clinically significant abnormal level of serum creatinine~* Patients whose occupations make them unlikely to return to the clinic within 24h of treatment initiation~* Pregnancy or breast-feeding~* Investigational drug or immunomodulator treatment in the 30 days prior randomisation~* Prior enrollment in this study~* Participation in another therapeutic trial evaluating new drugs or which could interfere with the evolution of herpes labialis or the evaluation of the drug in the study within preceding 30 day.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Acyclovir Lauriad 50mg
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Controlled Trial of Chinese Herbal Medicine to Treat Allergic Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria of the participants are:~1. Nursing students in a full-time bachelor degree program in School of Nursing at The University under study;~2. They are diagnosed by Western medicine and/or TCM practitioner with allergic rhinitis, including those seasonal or perennial one for at least two years;~3. They have a body constitution of Cold and Yang-Deficiency, according to the TCM assessment;~4. They are aged 18 or above and able to speak Cantonese and/or Mandarin; and~5. They can understand written Chinese language, particularly the questionnaires used.~Exclusion Criteria of these students include those who have:~1. A body constitution pattern of Hot and/or Yin-Deficiency, according to the TCM assessment;~2. Currently been taking long-term medications such as anti-hypertensive and psychiatric drugs;~3. Known medical history of co-morbidity of a recent acute and/or chronic disease such as heart, liver and lung disease, cancer, and/or mental illness;~4. Recently undergone major operation(s), are receiving chemotherapy and radiotherapy, or are going to be admitted into hospital over the study period; and~5. Known allergy history of Chinese herbal medicine .

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Cure-Allergic Rhinitis Syrup (Type: EXPERIMENTAL): In syrup form, 20 ml once daily for 4 weeks
- Yu-ping-fung San (Type: ACTIVE_COMPARATOR): In syrup form, 20ml once daily for 4 weeks
- Placebo group (Type: PLACEBO_COMPARATOR): In syrup form (wheat powder with ginger and flavors), 20 ml once daily for 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Investigating Treatment Factor X in People With Factor X Deficiency

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent given, or for subjects aged 12-17 years, have given written assent and whose parent/guardian has given written informed consent~* At least 12 years of age at dtae of written informed consent~* Have hereditary severe or moderate FX deficiency~* Currently treated with Fresh Frozen Plasma FFP, Prothrombin Complex Concentrate PCC or factor IX/X concentrate~* Must have a minimum of one spontaneous or menorrhagic bleed in the last 12 months which required treatment of FFP, PCC or factor IX/X concentrate. Newly diagnosed subjects who present at the hospital with a bleed may be included~* Must have had at least 7 days, and ideally 10-14 days, since an infusion of either FFP, PCC or factor IX/X concentrate at Baseline Visit~* Females of child bearing potential must have a negative result on a HCG based pregnancy test. If they are or become sexually active, they must practise contraception by using a method of proven reliability for the duration of the study~Exclusion Criteria:~* Have a history of inhibitor development to FX or a positive result at the Screening Visit~* Bleeding at the appointment for the PK assessment~* Subjects who have thrombocytopenia~* Have clinically significant liver disease~* Known to have other coagulopathy or thrombophilia~* Have known or suspected hypersensitivity to the investigational medicinal product or its excipients~* Have abused chemicals or drugs within the past 12 months~* Have a history of unreliability or non-cooperation~* Participating or have taken part in another trial within the last 30 days, with the exception of BPL FX surgery study - Protocol Ten03. In such cases, subjects should have completed their End of Study Visit either before or on the day of Screening Visit for this study~* Female subjects who are pregnant or lactating~* Subjects planning greater than 4 weeks absence from the locality of the Investigational site, between the screening visit and the repeat PK assessment

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Human Coagulation FACTOR X (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: High Dose PPI Triple Therapy Versus Sequential Therapy for Helicobacter Pylori Eradication

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Functional dyspepsia patients (Rome III) with rapid urease test positive~* Age ≥ 18 years old~* No history of HP eradication~Exclusion Criteria:~* Recent use of PPI, H2RA, NSAID, Antibiotics within 2 weeks~* Currently use of anticoagulants or ketoconazole~* C/I for gastric biopsy~* History of gastric surgery~* Comorbidity: ESRD, advanced cirrhosis, AIDS, stroke (bed ridden)~* Pregnancy or lactation~* Allergy to studied drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sequential therapy (ST) (Type: ACTIVE_COMPARATOR): 10 day Sequential therapy: lansoprazole 30 mg b.d. plus amoxicillin 1000 mg b.d. for 5 days then lansoprazole 30 mg b.d., metronidazole 400 mg b.d. and clarithromycin 500 mg b.d. for the remaining 5 days
- High dose PPI triple therapy(TT) (Type: EXPERIMENTAL): 10 day high dose PPI triple therapy: lansoprazole 60 mg b.d. plus clarithromycin 500 mg b.d. and amoxycillin 1000 mg b.d. for 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bunionectomy Study (0000-063)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is a man or woman between 18 and 65 years of age~* For Women of Child-bearing potential: woman who is currently not pregnant not nursing and who is willing to use a medically acceptable method of birth control from the time after the screening visit until completion of the follow-up visit~* Patient is scheduled to have a bunionectomy~* Patient must be willing to stay at the study site throughout the 48-hour observation period following surgery and is willing to complete a 2-week follow up~* Patient is capable of operating a Patient Controlled Analgesia device~Exclusion Criteria:~* Patient is being treated for a disease and has not been on a stable dose of medication for at least 2 weeks prior to surgery~* Patient has used or intends to use any of the medications that are prohibited by the protocol, which could interfere with the evaluation of the study drugs~* Patient has an estimated creatinine clearance of \< or = 60 mL per min~* Patient has a history of drug abuse or dependence, or patient has a positive urine drug screen~* Patient has a condition that prevents clear communication concerning pain perception (such as diabetic neuropathy, peripheral neuropathy, etc.)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1: Pregabalin 300 mg (Type: ACTIVE_COMPARATOR): None
- Arm 2: naproxen sodium 550 mg (Type: ACTIVE_COMPARATOR): None
- Arm 3: Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Fosamax Plus D in Postmenopausal Women With Osteoporosis (0217A-263)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient agrees to apply sunscreen and limit sunlight-exposure to 1 hour per day during the study~* Patient has been diagnosed with osteoporosis~* Patient has been postmenopausal for more than 6 months~* Patient has no contraindication to taking oral bisphosphonates~* Patient is eligible for dual energy x-ray absorptiometry in spine or hip~Exclusion Criteria:~* Patients with esophageal dysfunction~* Patients who can not sit or stand at least 30 minutes~* Patients who had a malignant disease or active systemic disease 5 years prior to participating in this trial~* Patients with diseases of bone or mineral metabolism besides osteoporosis or receiving therapies which affect bone metabolism or calcium metabolism~* Patients with history of major gastrointestinal disease (peptic ulcer, malabsorption, esophageal disease, gastritis, gastroduodenitis, etc.) within the last 6 months

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Alendronate sodium/Cholecalciferol
- 2 (Type: ACTIVE_COMPARATOR): Alendronate sodium

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have completed the final study visit in Study RHBV (NCT02696785), RHBW (NCT02696798), or RHBX (NCT02757352).~(Note: Participants from Study RHBX are not eligible if they permanently discontinued ixekizumab and were receiving a tumor necrosis factor \[TNF\] inhibitor).~* Must agree to use a reliable method of birth control.~Exclusion Criteria:~* Have significant uncontrolled disorders or abnormal laboratory values that, in the opinion of the investigator, pose an unacceptable risk to the participant if investigational product continues to be administered.~* Have a known hypersensitivity to ixekizumab or any component of this investigational product.~* Had investigational product permanently discontinued during a previous ixekizumab study.~* Had temporary investigational product interruption at any time during or at the final study visit of a previous ixekizumab study and, in the opinion of the investigator, restarting ixekizumab poses an unacceptable risk for the participant's participation in the study.~* Have any other condition that, in the opinion of the investigator, renders the participant unable to understand the nature, scope, and possible consequences of the study or precludes the participant from following and completing the protocol.~* Are currently enrolled in any other clinical trial involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ixekizumab (IXE) 80Q4W (Type: EXPERIMENTAL): Participants received 80 milligram (mg) of Ixekizumab subcutaneously (SC) every four weeks (Q4W).
- Ixekizumab (IXE) 80Q2W (Type: EXPERIMENTAL): Participants received 80 milligram (mg) of Ixekizumab subcutaneously (SC) every two weeks (Q2W).
- Placebo (Type: PLACEBO_COMPARATOR): Participants received subcutaneous dose of placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Exercise and Weight Loss in PAD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* BMI \>25 kg/m2~* Ankle Brachial Index (ABI) \<.90~* Able to participate in a supervised exercise program at the Baltimore VA~* No current plan for surgical revascularization~* Claudication or leg symptoms when walking~Exclusion Criteria:~* Unstable angina or a recent heart attack~* Active cancer~* Dementia~* Current foot or leg ulcers~* Already exercise 2x/week or more.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Exercise and Weight Loss (Type: EXPERIMENTAL): Individuals assigned to this group will be asked to complete both the exercise and weight loss intervention for six months
- Exercise (Type: ACTIVE_COMPARATOR): Individuals assigned to this group will be asked to complete the exercise intervention for xic months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TCH Versus EC-TH as Neoadjuvant Treatment for HER2-Positive Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed HER2 positive invasive breast carcinoma~* Clinical stage Ⅱ-ⅢC~* Eastern Cooperative Oncology Group(ECOG) performance status 0 to 1 within 14 days of study entry~* Normal (greater than 50%) left ventricular ejection fraction (LVEF) by echocardiography~* Signed informed consent~* Adequate organ function within 2 weeks of study entry:~Absolute neutrophil count \>1500/mm3, Hgb \>9.0 g/dl and platelet count \>100,000/mm3 Total bilirubin \< upper limit of normal Creatinine \< 1.5 mg/dL or calculated cranial cruciate ligament (CrCL) \>50mL/min using the Cockcroft Gault equation serum glutamate oxaloacetate transaminase(SGOT)(AST) or serum glutamic oxaloacetic transaminase(SGPT)(ALT) and Alkaline Phosphatase must be within the range allowing for eligibility~* Patients must be over 18 years old.~* Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment~* Women of childbearing potential and men must agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participation.~Exclusion Criteria:~* Metastatic disease~* Prior chemotherapy, hormonal therapy, biologic therapy, investigational agent, targeted therapy or radiation therapy for current breast cancer. Patients with history of breast cancer greater than 5 years from initial diagnosis are eligible for the study. Patients may not have received anthracycline-based chemotherapy in the past. Patients with history of ductal carcinoma in situ(DCIS) are eligible if there were treated with surgery alone.~* History of previous or current malignancy at other sites with the exception of adequately treated carcinoma in-situ of the cervix or basal or squamous cell carcinoma of the skin. Patients with a history of other malignancies, who remain disease free for greater than five years are eligible.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TCH (Type: EXPERIMENTAL): docetaxel/carboplatin/trastuzumab
- EC-TH (Type: ACTIVE_COMPARATOR): epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Basivertebral Nerve Ablation Treatment of Chronic Low Back Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Skeletally mature subjects at least 25 years of age~* Chronic low back pain for at least 6 months~* Failure to respond to at least 6 months of non-operative conservative management~* Oswestry Disability Index (ODI) at least 30 points~* Modic changes Type 1 or 2~Exclusion Criteria:~* Current or history of vertebral cancer or spinal metastasis~* History of a fragility fracture~* Any back pathology related to trauma, evidence of vertebral compression fracture or other spinal pathology that could affect assessment of response to back pain~* Disc extrusion or protrusion

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): BVN Ablation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has a history of genital HSV documented by laboratory testing at screening~* Subject has experienced 4 or more episodes of genital herpes during the past 12 months~Exclusion Criteria:~* Subject is immunocompromised

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Oral administration of active comparator
- 2 (Type: PLACEBO_COMPARATOR): Oral administration of placebo
- 3 (Type: EXPERIMENTAL): Dosing regimen 1
- 4 (Type: EXPERIMENTAL): Dosing regimen 2
- 5 (Type: EXPERIMENTAL): Dosing regimen 3
- 6 (Type: EXPERIMENTAL): Dosing regimen 4

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete